This content is for Healthcare Professionals only.

Please confirm that you are a healthcare professional.

Decline

This activity has been sponsored by GW Pharmaceuticals, plc. GW Pharmaceuticals, plc., provided financial support for this activity and has had input into the selection of the faculty and the detailed project scope. 

Epilepsy Watch Time: 46 mins (Part 1); 11 mins (Part 2)

touchLIVE MEETING Addressing unmet needs to improve outcomes for people with epilepsy

Keep up to date on the latest developments by watching this webinar discussing key issues in the treatment and management of severe epilepsy, focussing on:

  • The key unmet medical needs that still exist for people with severe epilepsy.
  • How the latest clinical trial results support emerging therapeutic options to address these unmet needs.
  • Challenges and insights that the COVID-19 pandemic has revealed about the diagnosis, treatment and management of people with epilepsy.

Part 1: Watch the webinar with three internationally renowned experts discussing key issues in the treatment and management of severe epilepsy Watch Now
Part 2: Watch the interview providing the highlights of the webinar Watch Now

  • Part 1: Webinar
Next Chapter
Introduction
Watch Time: 00:00
Key unmet medical needs that remain for people with epilepsy today
Watch Time: 04:53
PANEL DISCUSSION
Watch Time: 14:31
The impact of the COVID-19 pandemic in people with epilepsy: Additional burdens and barriers
Watch Time: 25:53
PANEL DISCUSSION
Watch Time: 36:14
Audience questions and close
Watch Time: 45:06
Video Player Controls:
 
Leave Feedback
Downloads

View and download resources from this activity to support your learning or share with colleagues.

  • Part 2: Expert Interview
Leave Feedback
Professor Ley Sander
Watch Time: 10:52
Professor of Neurology and Clinical Epilepsy, National Hospital for Neurology & Neurosurgery, Queen Square, London, UK

Professor Ley Sander discusses the challenges and unmet needs that people with epilepsy still face today, especially during the COVID-19 pandemic, and recent developments in the field that may help to address these challenges. 

 
Leave Feedback
Interview Questions

In this interview, Professor Ley Sander answers the following questions:

  • What are the main challenges and unmet needs in treating epilepsy?
  • In your opinion, what have been the most promising therapeutic developments in the past few years, and how do you think these might address these unmet needs?
  • How has the COVID-19 pandemic affected patient care and support?
  • Overall, what is the current outlook for patients with epilepsy that is refractory to conventional ASMs, and how can we further improve their quality of life?
Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview
  • Despite the availability of a wide variety of anti-epileptic drugs, there is still a clear unmet medical need; it is estimated that in 30–40% of all people with epilepsy, the disease is refractory to treatment, and patients continue to experience seizures1 
  • The COVID-19 pandemic has also raised additional challenges and barriers to the effective diagnosis and management of epilepsy and highlighted the need for appropriate support for both people with epilepsy and caregivers
  • For this touchLIVE MEETING webinar, three leading experts will be discussing key issues in the treatment and management of severe epilepsy, focussing on:
  1. The key unmet medical needs that still exist for people with severe epilepsy
  2. How the latest clinical trial results support emerging therapeutic options to address these unmet needs
  3. Challenges and insights that the COVID-19 pandemic has revealed about the diagnosis, treatment and management of people with epilepsy
Learning Objectives

After watching this activity, you should be able to:

  • Assess the main diagnostic approaches in epilepsy and the challenges that remain in the management and monitoring of the disease, particularly during the COVID-19 pandemic
  • Recognize the key medical unmet needs that remain for people with epilepsy, especially with conditions that are often refractory to conventional anti-epileptic drugs, such as encephalopathic epilepsies
  • Describe recent therapeutic developments in epilepsy, evaluate the supporting clinical evidence, and appreciate how they might impact quality of life beyond symptom control
Faculty & Disclosures
Professor Ley Sander

Professor of Neurology and Clinical Epilepsy, National Hospital for Neurology & Neurosurgery, Queen Square, London, UK

Ley Sander is Professor of Neurology and Clinical Epilepsy and Honorary Consultant Neurologist with a specialist interest in epilepsy.

read more

In this role, he has approximately 1,200 people with epilepsy under his neurological care. He heads the Department of Clinical and Experimental Epilepsy at the National Hospital for Neurology & Neurosurgery and is the Medical Director of the Chalfont Centre for Epilepsy in Buckinghamshire. Ley Sander is also the Scientific Director of Stichting Epilepsie Instellingen Nederland in Heemstede, the Netherlands. He qualified in medicine at the University of Parana in Curitiba, Brazil and then completed his specialist training in neurology at St Thomas Hospital and at the National Hospital for Neurology and Neurosurgery in London. He obtained his PhD in clinical neurosciences at the University of London and is an elected fellow of the Royal College of Physicians.

Disclosures: Professor Sander has received research grants from Medtronic and UCB, received honoraria as a speaker in virtual and presential events sponsored by Arvelle Therapeutics, Eisai, Novartis, UCB and Zogenix, and for participation on advisory boards for Arvelle, UCB and Zogenix. Professor Sander has, or his department has, undertaken, or are undertaking, studies funded by research grants from Medtronic and UCB. He has not, nor has any members of his family, owned shares or equities in pharmaceutical or medical device companies.

Dr Patricia Smeyers

Paediatric Neurologist, Hospital Infantil Universitario La Fe, Valencia, Spain

Dr Patricia Smeyers is working as a paediatric neurologist in Valencia (Spain), where she is in charge of paediatric epilepsy in the Multidisciplinary Epilepsy Unit at Hospital Universitario y Politécnico La Fe. This unit is a national and European (Epicare) reference centre for rare epilepsies and epilepsy surgery. 

read more

Dr Smeyers graduated in medicine and surgery in Valencia and achieved her doctoral thesis in genetics, researching the genetics of patients with Friedreich’s ataxia as part of the team that contributed to the discovery of the FA gene. She specializes in neurology and clinical neurophysiology and has been accredited in paediatric neurology and epileptology. She trained in both Göteborg University, Sweden, and King’s College, London. Dr Smeyers has presented more than 120 oral presentations at various scientific congresses and meetings, has written more than 100 national and international papers and book chapters, and has participated in many clinical trials and research projects in epilepsy. She is also the leader of the Epicaval network (A Regional Epilepsy Network for the Study and Research of Childhood Epilepsy) and contributes significantly towards addressing social and educational issues for children, parents and teachers through the publication of story tales on epilepsy, for which she received an award from the Spanish Neurology Society in 2012.

Disclosures:

Dr Smeyers has received honoraria for participation in advisory boards, talks and formative activities from Bial, Eisai, GW pharmaceuticals, Humana, Neuraxpharm and UCB.

Dr Pasquale Striano

Associate Professor, Università degli Studi di Genova, Genova, Italy

Dr Striano is actively involved in research projects in Italy, Europe and worldwide. He is a board member of Italian League Against Epilepsy (LICE), a scientific association that is focused on promoting knowledge of epilepsy among people and among physicians to improve the care of patients. The collaborative network of LICE is actively working on both International and European projects. 

read more

Dr Striano is an associate partner of the EUROEPINOMICS consortium for the study of genetic epilepsies through next-generation sequencing techniques. The project involves the sequencing of coding regions of the genome of patients with undiagnosed epileptic encephalopathies and familiar forms with dominant or recessive inheritance. Dr Striano has received The International League Against Epilepsy Young Investigator Award at the European Congress of Epileptology, London, November 2012. From 2013, he has been a member of the Pediatric Committee of Italian Medicines Agency.

Disclosures:

Dr Striano has received speaker fees and has participated in advisory boards for Biomarin, GW Pharmaceuticals and Zogenyx, and has received research funding from Eisai ENECTA BV, GW Pharmaceuticals and Kolfarma Srl.

References
References
  1. Laxer KD, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70.
Feedback Close
Feedback

Please provide feedback for this touchLIVE MEETING on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar